Enspryng, the latest drug to hit the market, was shown to be a safe and effective treatment for NMOSD in two 96-week clinical trials.
“Until last year, there were no FDA-approved treatments for patients with this rare, debilitating and sometimes fatal disease. Now there are three,” said Billy Dunn, MD, director of the office of neuroscience in the FDA’s Center for Drug Evaluation and Research.
Enspryng was developed by Genentech, a biotechnology company that received FDA clearance for its Evrysdi drug for spinal muscular atrophy earlier this month.
More articles on spine:
Medtronic Q1 spine revenue down 14% to $1.8B; CEO reports ‘faster than expected recovery’
Dr. Richard Berger: Potential for delays makes now ‘the best time to get surgery’
Total Orthopedics Sports & Spine, American Airlines gain EPA approval for COVID-19 surface cleanser
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
